How can recurrent respiratory tract infections in adults be prevented and managed?

Prevention and Management of Recurrent Respiratory Tract Infections in Adults

For adults with recurrent respiratory tract infections (≥3 infections per year), implement a stepwise approach starting with optimized airway clearance and treatment of underlying conditions, followed by long-term prophylactic antibiotics (azithromycin 250mg three times weekly as first-line), with escalation to inhaled antibiotics if infections persist despite oral prophylaxis 1.

Defining Recurrent Respiratory Tract Infections

Recurrent RTIs in adults are operationally defined as 3 or more infections per patient per year, though some evidence suggests using the mean value threshold (approximately 0.16 events/patient/year in general population) 2. These infections represent an imbalance between lung defense mechanisms and bacterial burden, with viral infections often initiating the cascade but bacterial complications driving recurrence 3.

Stepwise Management Algorithm

Step 1: Foundational Assessment and Optimization

Before initiating prophylactic antibiotics 1:

• Obtain sputum culture and mycobacterial status to guide antibiotic selection
• Optimize airway clearance techniques (particularly critical in bronchiectasis)
• Identify and treat associated conditions (COPD, immunodeficiency, structural lung disease)
• Assess for IgG subclass deficiency if infections are severe or unusually frequent

Step 2: Long-Term Oral Antibiotics (≥3 exacerbations/year)

Azithromycin is the preferred first-line prophylactic agent 1:

• Start with 250mg three times weekly (pragmatic dose balancing efficacy and adverse events)
• Titrate upward based on clinical response and tolerability
• This approach reduces infection frequency by 54-78%, duration by 42-79%, and antibiotic consumption by 38% in adults 4
• Remain on the same antibiotic rather than rotating monthly; change only if efficacy fails, guided by sensitivity results 1

Critical caveat: Prophylactic antibiotics should only be initiated by respiratory specialists 1.

Step 3: Add Inhaled Antibiotics (≥3 exacerbations/year despite oral prophylaxis)

• Perform bronchoprovocation challenge test when stable before starting inhaled antibiotics 1
• Combine long-term macrolide with long-term inhaled antibiotic
• Monitor for in vitro resistance, though this may not affect clinical efficacy 1

Step 4: Intravenous Antibiotics (≥5 exacerbations/year despite Steps 2-3)

• Consider regular IV antibiotics every 2-3 months for patients with repeated infections despite maximal oral and inhaled therapy 1

Special Populations and Considerations

Patients with IgG Subclass Deficiency

For adults with selective or combined IgG subclass deficiency without IgA deficiency experiencing ≥4 antibiotic-requiring RTIs per year 5:

• Immunoglobulin prophylaxis at approximately 100mg/kg/week achieves ≥50% reduction in infection frequency
• Effective across IgG1 (57% reduction), IgG2 (59%), IgG3 (63%), and combinations (61%)
• Efficacy maintained regardless of concomitant chronic lung disease

Patients with Bronchiectasis

The threshold for intervention may be lower than 3 exacerbations/year if 1:

• Patient remains symptomatic between exacerbations
• Exacerbations respond poorly to treatment
• Patient is immunosuppressed or at high risk for severe exacerbation

Patients with Underlying Lung Disease

No difference in prophylactic antibiotic response exists between patients with and without chronic lung diseases 5, so apply the same stepwise algorithm.

Monitoring and Safety

Review patients on long-term antibiotics every 6 months 1:

• Assess efficacy (reduction in infection frequency and severity)
• Monitor for toxicity (macrolide-related QT prolongation, hearing loss, GI effects)
• Evaluate continuing need
• Check sputum culture and sensitivity regularly

Prevention Strategies Beyond Antibiotics

While the strongest guideline evidence supports antibiotic prophylaxis 1, emerging research suggests adjunctive strategies:

• Physical activity and stress management interventions are under investigation for reducing RTI incidence 6
• Ribosomal immunostimulants (e.g., Ribomunyl) demonstrate 27-68% reduction in recurrences in some studies 3, 4, though this is not included in major guidelines

Common Pitfalls to Avoid

1. Starting prophylactic antibiotics without specialist consultation - This violates guideline recommendations and risks inappropriate use 1
2. Monthly antibiotic rotation - Evidence supports staying on the same effective antibiotic 1
3. Ignoring airway clearance optimization - This foundational step must precede antibiotic prophylaxis 1
4. Failing to obtain baseline cultures - Essential for guiding antibiotic selection and monitoring resistance 1
5. Not performing bronchoprovocation testing - Required before inhaled antibiotics to prevent bronchospasm 1

When to Consider Surgical Intervention

For patients with localized bronchiectasis whose symptoms remain uncontrolled despite optimized medical management by a bronchiectasis specialist, consider lung resection with multidisciplinary assessment 1.